富血小板血浆注射治疗膝骨关节炎的成本效果:马尔可夫决策分析
该研究采用马尔可夫模型分析55岁Kellgren-Lawrence II或III级膝骨关节炎患者,比较3次PRP注射延迟TKA与立即TKA的成本效果。从医疗付费方角度,立即TKA以更低成本获得更多QALYs而占优;从社会角度,PRP不具成本效果。PRP缺乏确立的临床疗效是主因,而非注射价格。
要点
- 从医疗付费方角度,立即TKA成本更低且QALYs更高,占优PRP延迟策略。
- 假设PRP注射成本728美元,任何<10年的延迟均不具成本效果。
- PRP可能对高围手术期并发症风险或翻修率高的患者有价值。
核心结论
- 考虑直接和非付费间接成本时,PRP注射不具成本效果。
- 阻止PRP具成本效果的主要因素不是每剂注射价格,而是缺乏确立的缓解疼痛、改善功能和延迟TKA的临床疗效。
- PRP可能对高围手术期并发症率、高TKA翻修率或术后结果较差的高风险患者有价值。
研究设计与样本
- 马尔可夫模型分析基线病例:55岁Kellgren-Lawrence II或III级膝骨关节炎患者,接受3次PRP注射延迟TKA 1年 versus 立即TKA。
- 包括医疗付费方和社会角度,转移概率来自72项研究的系统综述,QOL值来自Tufts大学成本效果分析注册库,成本来自Medicare报销方案。
- 进行单因素和双因素敏感性分析以及概率分析,变化PRP注射成本、TKA延迟间隔和TKA结果,共10,000次模拟。
主要发现
- 从医疗付费方角度,PRP组QALYs为14.55,立即TKA组为14.63;总医疗成本分别为26,619美元和26,235美元。
- 立即TKA以更低成本产生更高QALYs,故占优。
- 从社会角度,PRP成本49,090美元,立即TKA成本49,424美元;立即TKA的ICER为每QALY 4,175美元,低于50,000美元支付意愿阈值。
- 假设PRP注射公布成本728美元,任何<10年的延迟时间均不产生成本效果路径。
- 当QOL值从公布的0.788增至>0.89时,PRP治疗即使延迟TKA 1年也具成本效果。
关键数值与推荐
- 主要结局指标为总成本和质量调整生命年(QALYs),组织为增量成本效果比(ICERs),对照支付意愿阈值50,000美元和100,000美元。
- 从医疗付费方角度,PRP组QALYs 14.55,立即TKA组14.63;总医疗成本分别为26,619美元和26,235美元。
- 从社会角度,PRP成本49,090美元,立即TKA成本49,424美元;立即TKA的ICER为每QALY 4,175美元。
- 假设PRP注射成本728美元,无<10年的延迟时间产生成本效果路径。
- QOL值从0.788增至>0.89时,PRP治疗即使延迟TKA 1年也具成本效果。
临床怎么用
- 在考虑直接和非付费间接成本时,PRP注射治疗膝骨关节炎不具成本效果。
- PRP可能对高围手术期并发症率、高TKA翻修率或术后结果较差的高风险患者有价值。
- 临床决策应基于PRP缺乏确立的缓解疼痛、改善功能和延迟TKA的临床疗效。
局限性
- 证据水平为经济Level IV。
- 模型参数基于系统综述、注册库和报销方案,可能存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Use of platelet-rich-plasma (PRP) injections for treating knee osteoarthritis has increased over the past decade. We used cost-effectiveness analysis to evaluate the value of PRP in delaying the need for total knee arthroplasty (TKA). METHODS: We developed a Markov model to analyze the baseline case: a 55-year-old patient with Kellgren-Lawrence grade-II or III knee osteoarthritis undergoing a series of 3 PRP injections with a 1-year delay to TKA versus a TKA from the outset. Both health-care payer and societal perspectives were included. Transition probabilities were derived from systematic review of 72 studies, quality-of-life (QOL) values from the Tufts University Cost-Effectiveness Analysis Registry, and individual costs from Medicare reimbursement schedules. Primary outcome measures were total costs and quality-adjusted life years (QALYs), organized into incremental cost-effectiveness ratios (ICERs) and evaluated against willingness-to-pay thresholds of $50,000 and $100,000. One and 2-way sensitivity analyses were performed as well as a probabilistic analysis varying PRP-injection cost, TKA delay intervals, and TKA outcomes over 10,000 different simulations. RESULTS: From a health-care payer perspective, PRP resulted in 14.55 QALYs compared with 14.63 for TKA from the outset, with total health-care costs of $26,619 and $26,235, respectively. TKA from the outset produced a higher number of QALYs at a lower cost, so it dominated. From a societal perspective, PRP cost $49,090 versus $49,424 for TKA from the outset. The ICER for TKA from the outset was $4,175 per QALY, below the $50,000 willingness-to-pay threshold. Assuming the $728 published cost of a PRP injection, no delay time that was <10 years produced a cost-effective course. When the QOL value was increased from the published value of 0.788 to >0.89, PRP therapy was cost-effective with even a 1-year delay to TKA. CONCLUSIONS: When considering direct and unpaid indirect costs, PRP injections are not cost-effective. The primary factor preventing PRP from being cost-effective is not the price per injection but rather a lack of established clinical efficacy in relieving pain and improving function and in delaying TKA. PRP may have value for higher-risk patients with high perioperative complication rates, higher TKA revision rates, or poorer postoperative outcomes. LEVEL OF EVIDENCE: Economic Level IV. See Instructions for Authors for a complete description of levels of evidence.
引用
- Rajan PV, Ng MK, Klika A, et al. The Cost-Effectiveness of Platelet-Rich Plasma Injections for Knee Osteoarthritis: A Markov Decision Analysis. J Bone Joint Surg Am. 2020. PMID: 32453118. doi:10.2106/JBJS.19.01446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。